Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / Articles / Jul / The Epidemic That Cannot Be Ignored
Business & Regulation Business Practice Trends & Forecasts

The Epidemic That Cannot Be Ignored

Prescription drug abuse is not just a US problem.

By Charlotte Barker 07/29/2015 1 min read

Share

Two epidemics have touched the US in the past year. One highly publicized, the other much less so. Despite the media hysteria, the Ebola outbreak – which killed over 11,000 people, mostly in West Africa – resulted in only 10 cases and two deaths in the US. Compare that with recent figures on what the US Centers for Disease Control and Prevention (CDC) has officially declared an “epidemic of prescription drug abuse”:  16,000 deaths each year are caused by overdoses of prescription opioids – just one outcome of over 8 million Americans abusing prescription drugs, as we discover here. But, you say, “drug use and abuse is not a new phenomenon!”  That’s certainly true, but the sheer scale of prescription drug abuse – and the resulting fatalities – is shocking. For the areas worst affected by the epidemic, the impact on families and communities has been devastating.

Though the US has been hardest hit, it would be a mistake to think of this as an American problem. Prescription opioids are already amongst the most abused drugs in many countries, and European nonprofit drug policy foundation EURAD reports up to 1.9 million prescription drug addicts in Germany alone. Abuse-deterrent formulations are one part of the solution. Formulating commonly abused drugs so that they cannot be easily snorted or injected to give an instant hit, or including a substance that induces unpleasant side effects when taken in unhealthy quantities, may deter abuse at an early stage; for example, preventing patients from taking too much prescribed painkiller or steering their children away from experimenting with them. But people are ingenious. Determined addicts quickly overcome these measures or switch drugs. To see a real long-term impact, abuse-deterrent features need to be introduced in all frequently abused drugs – a goal that the FDA is working towards for the most abused opioids. New classes of drugs that fight pain without the euphoria and physical dependence of opioids would go a long way to solve the problem – but developing such compounds is easier said than done. Until then, a delicate balance must be struck between the right to effective pain relief and the devastation caused by addiction.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Charlotte Barker

As an Editor at Texere, I’m working closely with our audience to create vibrant, engaging content that reflects the hard work and passion that goes into bringing new medicines to market. I got my start in biomedical publishing as a commissioning editor for healthcare journals and have spent my career covering everything from early-stage research to clinical medicine, so I know my way around. And I can’t think of a more interesting, challenging or important area to be working in.

More Articles by Charlotte Barker

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.